RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Jiangsu Zecheng Biotech completed a $26 million C Round financing to support its in vitro diagnostic business that offers fully automatic chemiluminescence-based tests. The round was led by Hongtai Capital and included Wuxi Capital along with other firms. The funds will be used for R&D of new products and platform improvements. Zecheng Bio’s devices and reagents have been approved in China and the EU. Established in 2011, Zecheng sells its devices to secondary and tertiary hospitals in China and markets them in Asia, Latin America, Eastern Europe and Southern Europe. Source: China Biotoday
